Local Institution - 0238

Hangzhou, Zhejiang 310022

0 studies enrolling now · 2 studies all time

What they study most

Advanced Cancer, Breast Cancer

Studies at this site

• An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer — Completed
• Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer — Completed